Radiopharm Theranostics: Developing a portfolio of assets targeting cancer

Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company’s pipeline and discusses the recent licensing of an asset from UCLA.